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Objectives This study evaluated the safety of coronary reactivity testing (CRT) in symptomatic
women with evidence of myocardial ischemia and no obstructive coronary artery disease (CAD).
Background Microvascular coronary dysfunction (MCD) in women with no obstructive CAD por-
tends an adverse prognosis of a 2.5% annual major adverse cardiovascular event (MACE) rate. The
diagnosis of MCD is established by invasive CRT, yet the risk of CRT is unknown.
Methods The authors evaluated 293 symptomatic women with ischemia and no obstructive CAD,
who underwent CRT at 3 experienced centers. Microvascular function was assessed using a Doppler
wire and injections of adenosine, acetylcholine, and nitroglycerin into the left coronary artery.
CRT-related serious adverse events (SAEs), adverse events (AEs), and follow-up MACE (death, nonfatal
myocardial infarction [MI], nonfatal stroke, or hospitalization for heart failure) were recorded.
Results CRT-SAEs occurred in 2 women (0.7%) during the procedure: 1 had coronary artery dissec-
tion, and 1 developed MI associated with coronary spasm. CRT-AEs occurred in 2 women (0.7%) and
included 1 transient air microembolism and 1 deep venous thrombosis. There was no CRT-related
mortality. In the mean follow-up period of 5.4 years, the MACE rate was 8.2%, including
5 deaths (1.7%), 8 nonfatal MIs (2.7%), 8 nonfatal strokes (2.7%), and 11 hospitalizations for
heart failure (3.8%).
Conclusions In women undergoing CRT for suspected MCD, contemporary testing carries a rela-
tively low risk compared with the MACE rate in these women. These results support the use of CRT
by experienced operators for establishing deﬁnitive diagnosis and assessing prognosis in this at-risk
population. (Women’s Ischemia Syndrome Evaluation [WISE]; NCT00832702) (J Am Coll Cardiol Intv
012;5:646–53) © 2012 by the American College of Cardiology Foundation
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647In patients undergoing angiography for stable angina, the
proportion of women and men with no obstructive coronary
artery disease (CAD) is increasing over time (1). Compared
with men, women have a higher incidence of signs and
symptoms of myocardial ischemia, yet 30% to 50% of
women who undergo coronary angiography do not have
obstructive CAD (2–4). The absence of obstructive CAD is
not benign, as 38% of women with acute myocardial
infarction (MI) and no obstructive CAD have been found to
have plaque rupture or ulceration using intravascular ultra-
sound (5). Women with angina in the absence of obstructive
See page 654
CAD are often inappropriately reassured and even dis-
missed without further investigation or treatment: yet an-
gina among women, regardless of coronary angiographic
findings, is associated with increased mortality (6,7). The
National Heart, Lung, and Blood Institute–sponsored
WISE (Women’s Ischemia Syndrome Evaluation) studies
have documented that approximately one-half of these
symptomatic women with no obstructive CAD have micro-
vascular coronary dysfunction (MCD), which produces
ischemia and is associated with an adverse cardiovascular
prognosis compared with asymptomatic women (3,4,8–11).
Both coronary artery spasm and endothelial dysfunction
have been shown to be predictors of morbidity and mortality
in patients with angina (12–16). Coronary spasm may result in
I, ventricular arrhythmias, and sudden cardiac death
15,17,18). Recent data show that women without obstruc-
ive CAD who have a low coronary flow reserve (CFR) are
t higher risk of major adverse cardiac events (MACE)
ompared with those with normal CFR (19). Treatment
irected at endothelial function can reduce angina, coronary
pasm, heart failure, and stroke (20–23); therefore, it is
mportant to establish the diagnosis in order to institute
ppropriate medical management.
Invasive coronary reactivity testing (CRT) using vasoac-
ive agents to evaluate macrovascular and microvascular
esponses is considered the reference standard for a defini-
ive diagnosis of MCD (24). However, it is not routinely
erformed for a variety of reasons, including a lack of
tandardized protocols and concerns over catheterization
aboratory time. Furthermore, limited data exist on the
afety of contemporary CRT in women suspected of having
CD. We evaluated the safety of CRT performed at 3
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ethods
Women with angina and evidence of myocardial ischemia
underwent CRT at 3 experienced clinical centers that
participate in WISE: the University of Pittsburgh, the
University of Florida, Gainesville, and Cedars-Sinai Med-
ical Center. Inclusion criteria: women with angina, myocar-
dial ischemia by stress testing, and absence of obstructive
CAD (50% luminal obstruction in 1 or more epicardial
coronary arteries on angiography). Exclusion criteria: con-
traindications to angiography and invasive CRT (hypersen-
sitivity to contrast media, active bleeding, bleeding diathe-
sis, renal dysfunction); prior or planned percutaneous
coronary intervention or coro-
nary artery bypass grafting; acute
MI within 30 days; primary val-
vular heart disease; cardiogenic
shock or intra-aortic balloon
pump; inability to withhold ni-
trates, calcium channel agents,
and alpha- and beta-adrenergic
blockers for 24 h before testing;
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(Brown University). The institutional review boards at each
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648procedure. Pre-mixed acetylcholine in 3 concentrations
(0.182, 1.82, and 18.2 g/ml) was prepared within 3 h of
he scheduled procedures.
Outpatient diagnostic coronary angiography was per-
ormed via the percutaneous femoral approach. A pigtail
atheter was used to measure aortic and left ventricular
ressures. Patients with significant CAD, coronary artery
nomalies, or bridging were excluded. For borderline le-
ions, at the discretion of the interventionalist, intravascular
ltrasound and/or fractional flow reserve were used to
onfirm absence of obstructive stenosis.
After angiography, women were given body weight–
djusted heparin for anticoagulation, and the activated clotting
ime was maintained above 250 s. CRT was performed by
nfusing vasoactive substances through a guiding catheter
laced in the left main coronary artery. Doppler guidewire
0.014-inch diameter, FloWire, JOMED/Cardiometrics/
olcano, San Diego, California) was positioned in the proxi-
al left anterior descending coronary artery (Fig. 1). The
ollowing coronary functions were tested:
1. Nonendothelial-dependent microvascular function de-
termination: After an adequate flow reading was ob-
tained by the ComboMap Pressure and Flow System
(JOMED/Cardiometrics/Volcano), baseline average peak
velocity was recorded (Fig. 2). Intracoronary (IC) bolus
injections of incremental doses of adenosine (18 g,
18 g, and 36 g) were administered to create
maximal hyperemia. The catheter was flushed with
saline after each adenosine injection, and an average
peak velocity reading was obtained 5 s after the saline
flush. Adenosine CFR was calculated by ComboMap
as a ratio of average peak velocity to average baseline
velocity. This process was repeated and recorded for
each dose of adenosine after the peak velocity returned
Figure 1. Coronary Angiogram and CRT
The ﬁgure shows Doppler ﬂow wire in the left anterior descending artery (red arr
vasoconstriction (black arrows), indicating endothelial dysfunction (B). This is resolved bto baseline. A CFR2.5 in response to adenosine was
considered abnormal (14,19).
2. Endothelial-dependent microvascular and macrovas-
cular dysfunction determination: Graded IC acetyl-
choline concentrations of 0.182 and 18.2 g/ml were
infused (2 ml over 3 min). An intermediate dose of
1.82 g/ml was infused at the discretion of the
angiographer if it was deemed unsafe to proceed
directly to a higher dose of 18.2 g/ml, based on the
coronary reactivity from the lower dose (i.e., 0.182
g/ml) of acetylcholine. Doppler measurement of peak
velocity was obtained at the end of each acetylcholine
infusion. Normal endothelial-dependent microvascular
response was defined as a coronary blood flow increase
50% at the highest dose of acetylcholine. Post-
acetylcholine cine image was obtained for each concen-
tration for quantitative coronary angiography (QCA). We
ensured that coronary flow returned to baseline before
each infusion. Normal acetylcholine response, or
endothelial-dependent macrovascular coronary func-
tion, was defined as coronary artery dilation 5%.
Coronary blood flow response to acetylcholine was
calculated from the Doppler-derived time-velocity
integral and vessel diameter by the following equation:
Coronary blood flow   (average peak velocity/2)
(vessel diameter/2)2. Vessel diameter was calculated 5
mm distal to the Doppler wire.
3. Nonendothelial-dependent macrovascular function
determination: After completion of acetylcholine in-
fusions and the return of coronary flow velocity to
baseline, IC nitroglycerin (200 g) was injected to
evaluate nonendothelial-dependent macrovascular func-
tion. Average baseline and peak velocity were re-
corded. A cine image within 30 s of IC nitroglycerin
). In response to acetylcholine (ACH) infusion, there is abnormal coronary arteryow) (A
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649was obtained for QCA. Normal nitroglycerin response
was defined as a diameter increase 20%.
he angles, skew rotation, and table height were kept
onstant during the procedure. QCA measurements were
ade in the segment 5 mm distal to the tip of the Doppler
ire. For each time interval, the diameter was measured in
he same segment. Heart rate and blood pressure were
ecorded before and after administration of adenosine,
cetylcholine, and nitroglycerin.
Periprocedural adverse events. Adverse events (AEs) and
serious adverse events (SAEs) during and immediately
post-CRT were recorded. SAEs were defined as those that
required termination of the protocol and immediate hospi-
talization (hemodynamic instability, coronary artery dissec-
tion, MI, stroke, and death). AEs were defined as events
related to the procedure that did not require hospitalization
(such as deep venous thrombosis, transient coronary air
embolism, nonsustained arrhythmias, and transient hypo-
tension not requiring treatment). SAEs and AEs were
adjudicated by a clinical events committee.
Figure 2. Example of Doppler Wire Tracing
The ﬁgure depicts a coronary ﬂow velocity map showing an average peak velocit
mined by a Doppler ﬂow wire in the coronary artery. Adenosine tests nonendothe
based on the change in diameter of the vessel and the change in velocity in resp
Table 1. Patient Demographics (N  293)
White/Caucasian 247 (84%)
Age, yrs 54 10
History of smoking 140 (48%)
Dyslipidemia 94 (32%)
Hypertensive 102 (35%)
Diabetic 29 (10%)Values are n (%) or mean SD.Outcomes during follow-up. As per WISE protocol, women
ere followed up for 6 weeks and then annually for death,
onfatal MI, nonfatal stroke, and hospitalization for heart
ailure. The MACE rate was calculated as the percentage of
atients with a first event.
esults
The patient demographics are shown in Table 1. Results of
CRT are reported in Table 2; not all patients underwent all
aspects of reactivity testing, as this was site-dependent.
cm/s and a coronary ﬂow reserve of 2.8 in response to adenosine, as deter-
pendent microvascular vasodilatory capacity. Coronary blood ﬂow is calculated
o acetylcholine. Acetylcholine tests endothelial-dependent vasomotor function.
Table 2. Results of CRT
Abnormal nonendothelial microvascular function
(CFR 2.5 in response to 18 g of adenosine)
138/293 (47%)
Abnormal endothelial microvascular function
(50% change in CBF in response to
high-dose acetylcholine)
112/220 (51%)
bnormal endothelial macrovascular function
(5% increase in diameter in response to
high-dose acetylcholine)
127/220 (58%)
AAbnormal smooth muscle function (nonendothelial








(70% reduction in diameter to high-dose acetylcholine
compared with post-nitroglycerin diameter)
5/220 (2.3%)
Values are n/N (%).y of 39
lial-deCBF coronary blood flow; CFR coronary flow reserve; CRT coronary reactivity testing.
rction.
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650CRT-related SAEs occurred in 2 women (0.7%) and
included 1 coronary artery dissection (0.3%) and 1 ST-
segment elevation MI due to coronary artery spasm (0.3%)
(Table 3). CRT-related AEs occurred in 2 women (0.7%),
and included 1 with transient air microembolism (0.3%) and
1 with deep venous thrombosis on the side of the groin
access site (0.3%) 30 days after the CRT (Table 4). The
combined CRT-related AE/SAE rate was 1.4%. There was
no CRT-related mortality.
The prevalence of epicardial coronary vasospasm in our
women was 5%, when vasospasm was defined as acetylcho-
line response of 50% coronary artery diameter reduction
from baseline diameter (26). When defined as 70%
coronary artery diameter reduction to acetylcholine from
baseline, vasospasm occurred in 2 patients (0.9%). We also
compared acetylcholine response to post-nitroglycerin di-
ameter. Five patients (2.3%) had a 70% reduction in
diameter due to acetylcholine compared with their post-
nitroglycerin diameter.
The cohort was then followed for a period of 5.4 years,
with 32 MACE observed in 24 women, including 5 deaths
(1.7%), 8 nonfatal MIs (2.7%), 8 nonfatal strokes (2.7%),
and 11 hospitalizations for heart failure (3.8%). The com-
posite MACE rate to first event was 8.2% (24 of 293).
Discussion
Although invasive CRT is used to diagnose MCD in
patients without obstructive CAD, the safety of CRT has
not been well established, especially among women. The
results of our study demonstrate that invasive CRT is
Table 3. CRT-Related SAEs
Patient
Age (Yrs) Target Vessel Complication
53 LAD Before initiation of protocol, a focal spasm in
visualized while the Doppler wire was in th
causing an MI and prolonged chest pain.
58 LAD A nonﬂow-limiting coronary dissection of the
resulted from advancement of the Doppler
vasospasm and staining were visualized aft
acetylcholine injection. IC nitroglycerin app
dilated the vessel.
CPK  creatine phosphokinase; CRT  coronary reactivity testing; IC  intracoronary; LAD  le
MImyocardial infarction; SAE serious adverse event(s); TIMI Thrombolysis In Myocardial Infa
Table 4. CRT-Related AEs
Patient
Age (Yrs) Target Vessel Complication
66 LAD An air microembolism to RCA was notice
infusion catheter, causing chest pain f
52 LAD Patient was diagnosed with a deep veno
than 30 days after her coronary reactivAE adverse event(s); RCA right coronary artery; other abbreviations as in Table 3.relatively safe to evaluate MCD in symptomatic women
with evidence of ischemia but no obstructive CAD. Com-
pared with diagnostic coronary angiography, which carries a
2% risk of complications (26,27), addition of CRT does
not appear to significantly raise procedural risk. Specifically,
the combined CRT-related AE/SAE risk (1.4%) was sub-
stantially lower than the 5.4-year follow-up MACE rate
(8.2%). Prior studies have documented that MCD is asso-
ciated with an adverse cardiovascular prognosis compared
with asymptomatic women (3,4,8–10). Although clinical
trials testing whether medical therapy reduces MACE in
patients with MCD are needed, existing intermediate out-
come trials suggest that endothelial function improves with
treatment (20–23), as do signs and symptoms of ischemia
(28). Accordingly, establishment of the diagnosis of MCD
in these patients is important for appropriate medical
management.
Coronary blood flow is regulated by various endothelial-
dependent and nonendothelial-dependent factors. Non-
endothelial-dependent factors include myocardial metabo-
lism, myocardial compressive forces, aortic pressure, and
neurohumoral substances (29). We measured CFR directly
by the Doppler wire in response to adenosine, a
nonendothelial-dependent vasodilator (30). Acetylcholine
was used to test endothelium-dependent function, as it
stimulates nitric oxide release from the endothelial cells.
Nitroglycerin response was used to test nonendothelial-
dependent macrovascular function. Procedural success rates
were high in our study, and one-half of patients in our




Patient was given IC nitroglycerin and verapamil, as well as sublingual
and intravenous nitroglycerin. She was admitted with a peak CPK




TIMI ﬂow grade 3 was present, and no intervention was needed.
Patient was given clopidogrel and monitored overnight. She did
not experience additional chest pain. There were no
electrocardiographic changes.
rior descending coronary artery; LCX  left circumflex coronary artery; MB  myocardial band;
Treatment
g insertion of an
in.
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651Safety of IC Doppler ﬂow measurement. IC Doppler mea-
surement currently has a Class IIb recommendation for
assessment of the severity of coronary flow abnormalities in
patients with angina, ischemia by stress testing, but no
obstructive CAD (31). The Doppler wire used in our study
is a 0.014-inch-diameter flexible, steerable guidewire with a
piezoelectric ultrasound transducer integrated into the tip
(32,33). The Doppler wire may cause coronary spasm,
which was previously seen in 1% of patients undergoing IC
Doppler examination (34). Wire-induced spasm was re-
lieved by IC nitroglycerin, similar to our contemporary
study findings. A smaller study of 44 patients reported that
no Doppler wire–related complications occurred in patients
with normal or mild CAD (35). In our study, there was 1
coronary artery dissection (0.3%) that may have been due to
the Doppler wire. The dissection likely occurred during
placement of the Doppler wire before reactivity testing.
Focal vasospasm and staining of the mid left anterior
descending coronary artery were then noted during acetyl-
choline injection. No intervention was needed as the dis-
section was stable, with no limitation of flow.
Safety of IC adenosine. The safety and use of IC boluses of
denosine is well established (36–38). In a study of 39
atients by Wilson et al. (39), IC boluses (2 to 16 g)
roduced small, brief, dose-dependent reductions in mean
rterial pressure and did not significantly change the PR,
RS, or QT intervals on the electrocardiogram, even when
he drug was injected directly into the right coronary artery.
owever, in a study by Qian et al. (34) of 906 patients, 14
atients experienced arrhythmias (7 asystole, 4 second-
egree atrioventricular block, 1 third-degree atrioventricular
lock, 1 severe sinus bradycardia, 1 ventricular fibrillation),
ll of whom received an IC bolus of 12 g of adenosine in
the right coronary artery. One patient experienced sinus
bradycardia and hypotension after 18 g of IC adenosine in
he left anterior descending artery after stent implantation
34). In our study of 293 patients, neither the 18-g nor the
36-g dosages of adenosine resulted in any arrhythmias, and
ll cases were performed in the left coronary artery, showing
hat contemporary testing safety has improved and is safe.
Safety of IC acetylcholine. Acetylcholine has been used to
valuate coronary vasomotor function. Sueda et al. (40)
erformed 1,000 acetylcholine tests in Japanese men with
nd without obstructive CAD from 1991 to 2004. Incre-
ental doses of 20/50/80 g into the right coronary artery
and 20/50/100 g into the left coronary artery were injected
ver 20 s. They reported 17 of 1,000 patients (1.7%) who
xperienced a major adverse reaction during acetylcholine
nfusion, including 11 with nonsustained ventricular tachy-
ardia (1.1%), 1 with sustained ventricular tachycardia
0.1%), 1 with ventricular fibrillation (0.1%), 3 with shock
ue to left main stem spasm (0.3%), and 1 with cardiac
amponade (0.1%). No serious complications, such as death,
troke, or acute MI, were observed in this study.More recently, the CASPAR (Coronary Artery Spasm in
atients with Acute Coronary Syndrome) study investiga-
ors injected incremental doses of acetylcholine (2/20/100
g over 3 min) into the left coronary artery and/or right
coronary artery of 86 patients (15). Coronary vasospasm was
detected in 42 patients (49%). Ischemic ST-segment changes
were seen in 20 patients (17 ST-segment depressions, 3
ST-segment elevation), but there were no clinical adverse
events. In a study of nifedipine’s effect on endothelial dysfunc-
tion, investigators infused acetylcholine (0.36, 3.6, and 18
g/ml at 2 ml/min for 3 min) in either the left anterior
descending artery or circumflex artery of 641 patients (41).
Transient electrocardiographic changes were reported in 5
patients, whereas diffuse coronary vasoconstriction with hemo-
dynamic instability occurred in 5 patients (0.78%) (1 [0.16%]
required resuscitation). One patient (0.16%) developed acute
coronary syndrome and cardiac arrest in the catheterization
laboratory, possibly related to acetylcholine.
In our similarly sized study, acetylcholine infusions were
well tolerated, without significant hemodynamic changes,
again suggesting that contemporary testing safety has im-
proved. Although some patients did experience chest pain at
higher doses of acetylcholine, we were careful in monitoring
coronary flow throughout acetylcholine infusion to assess for
significant spasm. Five patients (2.3%) developed acetylcholine-
induced vasospasm, which immediately resolved after nitro-
glycerin injection, with no further sequelae. The higher
doses of acetylcholine used in the CASPAR study (2/20/
100 g) likely caused more coronary vasospasm than the
lower doses of acetylcholine used in our study (0.364/3.64/
36.4 g). Our case of coronary artery dissection was likely
ue to the Doppler wire rather than vasospasm from
cetylcholine.
Study limitations. As per WISE protocol, CRT was per-
formed in the left anterior descending coronary artery in all
patients. Safety of CRT in the right coronary artery or left
circumflex artery was not evaluated. Acetylcholine is not
directly infused into the left anterior descending artery, but
rather infused through the guiding catheter in the left main
coronary artery, and thus the concentration of the acetyl-
choline may be diluted in the left anterior descending artery.
Because vasoactive substances are infused in the left main
artery, both the circumflex and the left anterior descending
artery are susceptible to vasoconstrictive effects. The proto-
col stipulated for the Doppler wire to be maintained in the
proximal left anterior descending coronary artery. There-
fore, the safety of CRT when the Doppler wire is placed
more distally is unknown. It is also difficult to accurately
perform QCA in distal vessels due to their smaller diameter.
Conclusions
In women undergoing CRT for suspected MCD, contem-
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652when using standardized protocols for IC adenosine, ace-
tylcholine, and nitroglycerin delivery in experienced centers.
These results support the use of CRT by experienced
operators for diagnostic and prognostic purposes in patients
with persistent angina, evidence of myocardial ischemia, and
no obstructive CAD. Prior studies investigating therapy
directed at improvement of MCD have shown reduction of
angina, vasospasm, heart failure, and stroke. Additional
studies are needed to demonstrate improvement in cardio-
vascular outcomes.
Reprint requests and correspondence: Dr. C. Noel Bairey Merz,
Division of Cardiology, Women’s Heart Center, Cedars-Sinai
Medical Center, 444 South San Vicente Boulevard, Suite 600, Los
Angeles, California 90048. E-mail: merz@cshs.org.
REFERENCES
1. Jespersen L, Hvelplund A, Abildstrom SZ, et al. Stable angina pectoris
with no obstructive coronary artery disease is associated with increased risks
of major adverse cardiovascular events. Eur Heart J 2012;33:734–44.
2. Anderson RD, Pepine CJ. Gender differences in the treatment for
acute myocardial infarction: bias or biology? Circulation 2007;115:
823–6.
3. Reis SE, Holubkov R, Conrad Smith AJ, et al. Coronary microvascular
dysfunction is highly prevalent in women with chest pain in the absence
of coronary artery disease: results from the NHLBI WISE study. Am
Heart J 2001;141:735–41.
4. Shaw LJ, Bugiardini R, Merz CN. Women and ischemic heart disease:
evolving knowledge. J Am Coll Cardiol 2009;54:1561–75.
5. Reynolds HR, Srichai MB, Iqbal SN, et al. Mechanisms of myocardial
infarction in women without angiographically obstructive coronary
artery disease. Circulation 2011;124:1414–25.
6. Carpiuc KT, Wingard DL, Kritz-Silverstein D, Barrett-Connor E.
The association of angina pectoris with heart disease mortality among
men and women by diabetes status: the Rancho Bernardo study.
J Womens Health (Larchmt) 2010;19:1433–9.
7. Hemingway H, Langenberg C, Damant J, Frost C, Pyörälä K,
Barrett-Connor E. Prevalence of angina in women versus men: a
systematic review and meta-analysis of international variations across
31 countries. Circulation 2008;117:1526–36.
8. Johnson BD, Shaw LJ, Pepine CJ, et al. Persistent chest pain predicts
cardiovascular events in women without obstructive coronary artery
disease: results from the NIH-NHLBI-sponsored Women’s Ischaemia
Syndrome Evaluation (WISE) study. Eur Heart J 2006;27:1408–15.
9. von Mering GO, Arant CB, Wessel TR, et al. Abnormal coronary
vasomotion as a prognostic indicator of cardiovascular events in
women: results from the National Heart, Lung, and Blood Institute-
Sponsored Women’s Ischemia Syndrome Evaluation (WISE). Circu-
lation 2004;109:722–5.
0. Gulati M, Cooper-DeHoff RM, McClure C, et al. Adverse cardiovas-
cular outcomes in women with nonobstructive coronary artery disease:
a report from the Women’s Ischemia Syndrome Evaluation Study and
the St James Women Take Heart Project. Arch Intern Med 2009;169:
843–50.
1. Lanza GA, Buffon A, Sestito A, et al. Relation between stress-induced
myocardial perfusion defects on cardiovascular magnetic resonance and
coronary microvascular dysfunction in patients with cardiac syndrome
X. J Am Coll Cardiol 2008;51:466–72.
2. Halcox JP, Schenke WH, Zalos G, et al. Prognostic value of coronary
vascular endothelial dysfunction. Circulation 2002;106:653–8.
3. Schächinger V, Britten MB, Zeiher AM. Prognostic impact of coro-
nary vasodilator dysfunction on adverse long-term outcome of coronary
heart disease. Circulation 2000;101:1899–906.14. Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR Jr.,
Lerman A. Long-term follow-up of patients with mild coronary artery
disease and endothelial dysfunction. Circulation 2000;101:948–54.
15. Ong P, Athanasiadis A, Hill S, Vogelsberg H, Voehringer M, Sechtem
U. Coronary artery spasm as a frequent cause of acute coronary
syndrome: the CASPAR (Coronary Artery Spasm in Patients With
Acute Coronary Syndrome) study. J Am Coll Cardiol 2008;52:523–7.
16. Wakabayashi K, Suzuki H, Honda Y, et al. Provoked coronary spasm
predicts adverse outcome in patients with acute myocardial infarction:
a novel predictor of prognosis after acute myocardial infarction. J Am
Coll Cardiol 2008;52:518–22.
17. Sovari AA, Cesario D, Kocheril AG, Brugada R. Multiple episodes of
ventricular tachycardia induced by silent coronary vasospasm. J Interv
Card Electrophysiol 2008;21:223–6.
18. MacAlpin RN. Cardiac arrest and sudden unexpected death in variant
angina: complications of coronary spasm that can occur in the absence
of severe organic coronary stenosis. Am Heart J 1993;125:1011–7.
19. Pepine CJ, Anderson RD, Sharaf BL, et al. Coronary microvascular
reactivity to adenosine predicts adverse outcome in women evaluated
for suspected ischemia results from the National Heart, Lung and
Blood Institute WISE (Women’s Ischemia Syndrome Evaluation)
study. J Am Coll Cardiol 2010;55:2825–32.
20. Bonetti PO, Barsness GW, Keelan PC, et al. Enhanced external
counterpulsation improves endothelial function in patients with symp-
tomatic coronary artery disease. J Am Coll Cardiol 2003;41:1761–8.
21. Modena MG, Bonetti L, Coppi F, Bursi F, Rossi R. Prognostic role of
reversible endothelial dysfunction in hypertensive postmenopausal
women. J Am Coll Cardiol 2002;40:505–10.
22. Yasue H, Mizuno Y, Harada E, et al. Effects of a 3-hydroxy-3-
methylglutaryl coenzyme A reductase inhibitor, fluvastatin, on coronary
spasm after withdrawal of calcium-channel blockers. J Am Coll Cardiol
2008;51:1742–8.
23. Pauly DF, Johnson BD, Anderson RD, et al. In women with symptoms
of cardiac ischemia, nonobstructive coronary arteries, and microvascular
dysfunction, angiotensin-converting enzyme inhibition is associated with
improved microvascular function: a double-blind randomized study from
the National Heart, Lung and Blood Institute Women’s Ischemia Syn-
drome Evaluation (WISE). Am Heart J 2011;162:678–84.
24. Lerman A, Zeiher AM. Endothelial function: cardiac events. Circula-
tion 2005;111:363–8.
25. Bairey Merz CN, Shaw LJ, Reis SE, et al. Insights from the
NHLBI-Sponsored Women’s Ischemia Syndrome Evaluation (WISE)
study: part II: gender differences in presentation, diagnosis, and
outcome with regard to gender-based pathophysiology of atheroscle-
rosis and macrovascular and microvascular coronary disease. J Am Coll
Cardiol 2006;47:S21–9.
26. Scanlon PJ, Faxon DP, Audet AM, et al. ACC/AHA guidelines for
coronary angiography: a report of the American College of Cardiology/
American Heart Association Task Force on Practice Guidelines,
(Committee on Coronary Angiography). J Am Coll Cardiol 1999;
33:1756 – 824.
27. Kennedy JW. Complications associated with cardiac catheterization
and angiography. Cathet Cardiovasc Diagn 1982;8:5–11.
28. Mehta PK, Goykhman P, Thomson LE, et al. Ranolazine improves
angina in women with evidence of myocardial ischemia but no
obstructive coronary artery disease. J Am Coll Cardiol Img 2011;4:
514–22.
29. Bugiardini R, Bairey Merz CN. Angina with “normal” coronary
arteries: a changing philosophy. JAMA 2005;293:477–84.
30. Abebe W, Makujina SR, Mustafa SJ. Adenosine receptor-mediated
relaxation of porcine coronary artery in presence and absence of
endothelium. Am J Physiol 1994;266:H2018–25.
31. Scanlon PJ, Faxon DP, Audet AM, et al. ACC/AHA guidelines for
coronary angiography: executive summary and recommendations. A
report of the American College of Cardiology/American Heart Asso-
ciation Task Force on Practice Guidelines (Committee on Coronary
Angiography). Circulation 1999;99:2345–57.
32. Doucette JW, Corl PD, Payne HM, et al. Validation of a Doppler
guide wire for intravascular measurement of coronary artery flow
velocity. Circulation 1992;85:1899–911.
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 5 , N O . 6 , 2 0 1 2 Wei et al.
J U N E 2 0 1 2 : 6 4 6 – 5 3 Safety of Coronary Reactivity Testing
65333. Bach RG, Kern MJ. Practical coronary physiology. Clinical application
of the Doppler flow velocity guide wire. Cardiol Clin 1997;15:77–99.
34. Qian J, Ge J, Baumgart D, et al. Safety of intracoronary Doppler flow
measurement. Am Heart J 2000;140:502–10.
35. Mechem C, Kern MJ, Aguirre F, Cauley M, Stonner T. Safety and
outcome of angioplasty guidewire Doppler instrumentation in patients
with normal or mildly diseased coronary arteries (abstr). Circulation 1992;
86:I323.
36. Rieber J, Jung P, Schiele TM, et al. Safety of FFR-based treatment
strategies: the Munich experience. Z Kardiol 2002;91 Suppl 3:115–9.
37. Jeremias A, Whitbourn RJ, Filardo SD, et al. Adequacy of intra-
coronary versus intravenous adenosine-induced maximal coronary
hyperemia for fractional flow reserve measurements. Am Heart J 2000;
140:651–7.38. De Bruyne B, Pijls NH, Barbato E, et al. Intracoronary and
intravenous adenosine 5’-triphosphate, adenosine, papaverine, and mcontrast medium to assess fractional flow reserve in humans. Circulation
2003;107:1877–83.
39. Wilson RF, Wyche K, Christensen BV, Zimmer S, Laxson DD.
Effects of adenosine on human coronary arterial circulation. Circulation
1990;82:1595–606.
40. Sueda S, Oshita A, Nomoto T, et al. Recommendations for performing
acetylcholine tests safely: STOP Dangerous Complications Induced by
Acetylcholine Tests (STOP DCIAT). J Cardiol 2008;51:131–4.
41. Lüscher TF, Pieper M, Tendera M, et al. A randomized placebo-
controlled study on the effect of nifedipine on coronary endothelial
function and plaque formation in patients with coronary artery disease:
the ENCORE II study. Eur Heart J 2009;30:1590–7.
KeyWords: coronary reactivity  endothelial dysfunction 
icrovascular dysfunction.
